MassMutual Private Wealth & Trust’s CRISPR Therapeutics CRSP Stock Holding History

MassMutual Private Wealth & Trust’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$436	Hold	8	–	–	﹤0.01%	2292
2026 Q1	$381	Sell	8 -13	-62%	-$686	﹤0.01%	2274
2025 Q4	$1.1K	Buy	+21	New	+$1.26K	﹤0.01%	2123
2023 Q4	–	Sell	-49	Closed	-$2.22K	–	1978
2023 Q3	$2.22K	Buy	+49	New	+$2.53K	﹤0.01%	1479
2022 Q1	–	Sell	-178	Closed	-$13K	–	1537
2021 Q4	$13K	Sell	178 -120	-40%	-$10.5K	﹤0.01%	671
2021 Q3	$33K	Sell	298 -88	-23%	-$11.1K	﹤0.01%	532
2021 Q2	$62K	Sell	386 -45	-10%	-$5.47K	﹤0.01%	450
2021 Q1	$53K	Buy	431 +12	+3%	+$1.81K	﹤0.01%	429
2020 Q4	$64K	Buy	419 +204	+95%	+$24.1K	﹤0.01%	427
2020 Q3	$18K	Sell	215 -24	-10%	-$2.13K	﹤0.01%	509
2020 Q2	$18K	Hold	239	–	–	﹤0.01%	480
2020 Q1	$10K	Hold	239	–	–	﹤0.01%	517
2019 Q4	$15K	Buy	239 +30	+14%	+$1.64K	﹤0.01%	557
2019 Q3	$9K	Buy	209 +134	+179%	+$6.4K	﹤0.01%	601
2019 Q2	$4K	Hold	75	–	–	﹤0.01%	665
2019 Q1	$2.68K	Hold	75	–	–	﹤0.01%	756
2018 Q4	$2.14K	Buy	+75	New	+$2.61K	﹤0.01%	822

Other funds holding CRSP

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

EWA

EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Slow Capital Greenbrae, California $857M AUM 38.3% 1-Year Est. Return

CIA

Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return

SOMRS

State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

MassMutual Private Wealth & Trust's CRSP Position: Q2 2026 in Review

MassMutual Private Wealth & Trust held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 8 shares worth $436. The position accounts for ﹤0.01% of the portfolio, ranked #2292.

MassMutual Private Wealth & Trust first reported a position in CRSP in Q4 2018 and has held it in 17 quarters since. The position peaked at $64K in Q4 2020. 167 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

MassMutual Private Wealth & Trust held 8 shares of CRISPR Therapeutics worth $436 as of Q2 2026.
MassMutual Private Wealth & Trust left its CRISPR Therapeutics share count unchanged in Q2 2026.
CRISPR Therapeutics made up ﹤0.01% of MassMutual Private Wealth & Trust's portfolio in Q2 2026, its #2292 holding.
MassMutual Private Wealth & Trust first reported a position in CRISPR Therapeutics in Q4 2018 and has held it in 17 quarters since.
MassMutual Private Wealth & Trust's CRISPR Therapeutics position peaked at $64K in Q4 2020.
167 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on MassMutual Private Wealth & Trust's 13F filing for Q2 2026, filed 2 Jul 2026.